Neumora Therapeutics, Inc.
$2.19
▼
-4.31%
2026-04-21 08:26:00
www.neumoratx.com
NMS: NMRA
Explore Neumora Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$391.39 M
Current Price
$2.19
52W High / Low
$3.65 / $0.61
Stock P/E
—
Book Value
$0.6
Dividend Yield
—
ROCE
-152.06%
ROE
-1.21%
Face Value
—
EPS
$-1.45
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
96
Beta
3.12
Debt / Equity
52.96
Current Ratio
5.87
Quick Ratio
5.87
Forward P/E
-2.21
Price / Sales
—
Enterprise Value
$243.84 M
EV / EBITDA
-1.03
EV / Revenue
—
Rating
Buy
Target Price
$8.91
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Nkarta, Inc. | $3.49 | — | $247.38 M | — | -31.94% | -28.9% | $3.48 / $1.63 | $4.39 |
| 2. | Jupiter Neurosciences, Inc. | $0.46 | — | $15.86 M | — | -73.72% | -7.39% | $3.33 / $0.31 | $0 |
| 3. | CNS Pharmaceuticals, Inc. | $2.69 | — | $2.06 M | — | -241.26% | -2.96% | $34.8 / $2.06 | $17.25 |
| 4. | Enlivex Ltd. | $0.88 | — | $207.92 M | — | -0.65% | 1.26% | $2.1 / $0.66 | $8.15 |
| 5. | Q32 Bio Inc. | $6.65 | 3.26 | $97.29 M | — | 33.52% | 1.25% | $8.04 / $1.34 | $3.27 |
| 6. | Zymeworks Inc. | $27.85 | — | $1.98 B | — | -30.42% | -26.72% | $28.49 / $10.86 | $3.6 |
| 7. | Scholar Rock Holding Corporation | $47.8 | — | $5.49 B | — | -110.26% | -1.23% | $51.62 / $27.07 | $2.26 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -58.48 M | -57.7 M | -54.04 M | -70.94 M | -62.92 M | — |
| Net Profit | -59.45 M | -56.76 M | -52.73 M | -67.99 M | -58.82 M | — |
| EPS in Rs | -0.33 | -0.31 | -0.29 | -0.37 | -0.32 | -0.45 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -241.16 M | -263.46 M | -252.1 M | -135.87 M |
| Net Profit | -236.93 M | -243.79 M | -235.93 M | -130.9 M |
| EPS in Rs | -1.3 | -1.34 | -1.3 | -0.72 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 191.05 M | 316.97 M | 496.19 M | 426.23 M |
| Total Liabilities | 87.18 M | 29.91 M | 27.12 M | 873.08 M |
| Equity | 103.87 M | 287.06 M | 469.08 M | -446.85 M |
| Current Assets | 190.54 M | 314.06 M | 478.28 M | 387.95 M |
| Current Liabilities | 32.45 M | 29.89 M | 25.11 M | 23.7 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -206.44 M | -182.94 M | -163.28 M | -114.9 M |
| Investing CF | 168.52 M | -70.56 M | 64.39 M | -168.01 M |
| Financing CF | 77.09 M | 21.6 M | 231.94 M | 115.74 M |
| Free CF | -206.44 M | -182.94 M | -163.4 M | -115.41 M |
| Capex | — | — | -0.12 M | -0.51 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 2.81% | -3.33% | -80.23% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.